Corcept Therapeutics Shareholder Class Action Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 19 2026
0mins
Source: Globenewswire
- Lawsuit Deadline: Hagens Berman reminds investors in Corcept Therapeutics that April 21, 2026, is the critical deadline to apply as Lead Plaintiff, urging those who suffered losses to submit their claims promptly.
- Concealed FDA Warnings: The lawsuit alleges that Corcept failed to disclose significant facts regarding its lead drug candidate, relacorilant, during communications with the FDA, misleading investors about the drug's approval prospects.
- Market Crash Impact: Following the announcement of receiving a Complete Response Letter (CRL) from the FDA on December 31, 2025, Corcept's stock plummeted from $70.20 to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, reflecting severe market disappointment.
- Information Gap Allegations: The complaint asserts that Corcept's management was aware of the clinical data's flaws yet continued to project optimism about approval, creating a significant information gap that may have led to substantial investor losses.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 59.690
Low
50.00
Averages
91.00
High
121.00
Current: 59.690
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Corcept Therapeutics Stock Rises 7% After UBS Upgrade to Buy
- Rating Upgrade: UBS Group upgraded Corcept Therapeutics from Neutral to Buy, resulting in a more than 7% stock increase on Wednesday, indicating market optimism regarding its future performance.
- Price Target Increase: UBS raised its price target from $44 to $72, implying nearly a 41% upside from Tuesday's close of $51.16, reflecting analysts' confidence in the company's growth potential.
- Revenue Expectations: Analysts anticipate that the approval of Lifyoril for ovarian cancer will generate $936 million in peak PROC revenue, while Korlym sales are projected to reach $897 million by 2030, 17% above consensus, showcasing the company's competitive position in the market.
- Market Performance: Corcept Therapeutics' stock has gained over 58% year-to-date, significantly outperforming the S&P 500's 8% increase, indicating strong performance in the biopharmaceutical sector and investor confidence.
See More
Wall Street's Latest Ratings Overview
- Nvidia's Positive Outlook: Oppenheimer reiterates Nvidia as an outperform, projecting CY26 free cash flow to approach $200 billion, and if half is allocated for dividends, the yield could reach nearly 2.5%, which would bolster investor confidence and drive stock price appreciation.
- Apple's Strong Ecosystem: Daiwa raises Apple's price target from $310 to $325, emphasizing its vast ecosystem as a core strength, while acknowledging potential memory management challenges in 2H CY26, the long-term outlook remains favorable for this core holding.
- Positive Outlook for Housing Platform: UBS upgrades KE Holdings to buy from neutral, citing significant upside due to its agency business in tier 1 cities, particularly as the market recovery is led by the secondary market, positioning the company for strong performance.
- Wendy's Potential Privatization: Argus upgrades Wendy's to buy from neutral, driven by news of a potential move to take the restaurant chain private, with Trian Fund Management owning about 40% of the stock, indicating strong market confidence in this strategic shift.
See More
John Hussman's Q1 2026 Investment Moves Revealed
- New Stock Additions: John Hussman added a total of 97 stocks in Q1 2026, with Ulta Beauty Inc being the largest addition at 7,350 shares valued at $3.84 million, representing 0.83% of the portfolio, indicating confidence in the beauty sector.
- Key Position Increases: Hussman increased his stake in Corcept Therapeutics Inc by 94,500 shares, a significant 300% increase, bringing total holdings to 126,000 shares valued at $5.08 million, reflecting strong bullish sentiment towards the biopharmaceutical company.
- Complete Exits: Hussman exited 81 holdings in Q1, including Qualcomm Inc and Charter Communications Inc, which impacted the portfolio by -1.13% and -0.95% respectively, demonstrating a cautious approach towards these tech stocks.
- Portfolio Overview: As of Q1 2026, Hussman's portfolio comprised 268 stocks, primarily concentrated across 11 industries including healthcare, technology, and consumer goods, showcasing a diversified investment strategy to mitigate market fluctuations.
See More
Corcept Therapeutics Reports Q1 2026 Earnings and Raises Revenue Guidance
- Revenue Growth: Corcept Therapeutics reported Q1 2026 revenue of $164.9 million, up from $157.2 million in the prior year, indicating sustained market demand that is expected to enhance future profitability.
- Guidance Upgrade: Management raised the 2026 revenue guidance to $950 million to $1.05 billion, primarily driven by strong performance in the endocrinology business and the new oncology drug Lifyorli, reflecting confidence in future growth.
- FDA Approval Impact: Lifyorli was included in the National Comprehensive Cancer Network (NCCN) guidelines just 15 days post-FDA approval, which is expected to accelerate market adoption and enhance the company's competitiveness in oncology.
- Long-term Growth Outlook: Management anticipates that the Cushing's Syndrome business will reach at least $2 billion in annual revenue by 2030, while Lifyorli is expected to exceed $1 billion in annual revenue in the U.S., demonstrating strong confidence in future market potential.
See More
CORCEPT THERAPEUTICS INC ANTICIPATES PROFITABILITY BY Q2 2026
Company Overview: Corcept Therapeutics is anticipating a return to profitability in the second quarter of 2026.
Financial Expectations: The company is focusing on strategies to enhance its financial performance and achieve sustainable growth.
See More
Corcept Lawsuit Reminder for Investors
- Lawsuit Timeline: Rosen Law Firm reminds investors who purchased Corcept (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors can join the class action without any upfront fees or costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Case Background: The lawsuit alleges that Corcept made false statements regarding the confidence in FDA approval for its drug relacorilant, despite the FDA expressing concerns about the adequacy of clinical evidence, which exposed investors to potential losses.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved multiple large settlements, recovering over $438 million for investors in 2019 alone, demonstrating its expertise and successful track record in this field.
See More
Corcept Therapeutics Stock Rises 7% After UBS Upgrade to Buy
- Rating Upgrade: UBS Group upgraded Corcept Therapeutics from Neutral to Buy, resulting in a more than 7% stock increase on Wednesday, indicating market optimism regarding its future performance.
- Price Target Increase: UBS raised its price target from $44 to $72, implying nearly a 41% upside from Tuesday's close of $51.16, reflecting analysts' confidence in the company's growth potential.
- Revenue Expectations: Analysts anticipate that the approval of Lifyoril for ovarian cancer will generate $936 million in peak PROC revenue, while Korlym sales are projected to reach $897 million by 2030, 17% above consensus, showcasing the company's competitive position in the market.
- Market Performance: Corcept Therapeutics' stock has gained over 58% year-to-date, significantly outperforming the S&P 500's 8% increase, indicating strong performance in the biopharmaceutical sector and investor confidence.
See More
Wall Street's Latest Ratings Overview
- Nvidia's Positive Outlook: Oppenheimer reiterates Nvidia as an outperform, projecting CY26 free cash flow to approach $200 billion, and if half is allocated for dividends, the yield could reach nearly 2.5%, which would bolster investor confidence and drive stock price appreciation.
- Apple's Strong Ecosystem: Daiwa raises Apple's price target from $310 to $325, emphasizing its vast ecosystem as a core strength, while acknowledging potential memory management challenges in 2H CY26, the long-term outlook remains favorable for this core holding.
- Positive Outlook for Housing Platform: UBS upgrades KE Holdings to buy from neutral, citing significant upside due to its agency business in tier 1 cities, particularly as the market recovery is led by the secondary market, positioning the company for strong performance.
- Wendy's Potential Privatization: Argus upgrades Wendy's to buy from neutral, driven by news of a potential move to take the restaurant chain private, with Trian Fund Management owning about 40% of the stock, indicating strong market confidence in this strategic shift.
See More
John Hussman's Q1 2026 Investment Moves Revealed
- New Stock Additions: John Hussman added a total of 97 stocks in Q1 2026, with Ulta Beauty Inc being the largest addition at 7,350 shares valued at $3.84 million, representing 0.83% of the portfolio, indicating confidence in the beauty sector.
- Key Position Increases: Hussman increased his stake in Corcept Therapeutics Inc by 94,500 shares, a significant 300% increase, bringing total holdings to 126,000 shares valued at $5.08 million, reflecting strong bullish sentiment towards the biopharmaceutical company.
- Complete Exits: Hussman exited 81 holdings in Q1, including Qualcomm Inc and Charter Communications Inc, which impacted the portfolio by -1.13% and -0.95% respectively, demonstrating a cautious approach towards these tech stocks.
- Portfolio Overview: As of Q1 2026, Hussman's portfolio comprised 268 stocks, primarily concentrated across 11 industries including healthcare, technology, and consumer goods, showcasing a diversified investment strategy to mitigate market fluctuations.
See More
Corcept Therapeutics Reports Q1 2026 Earnings and Raises Revenue Guidance
- Revenue Growth: Corcept Therapeutics reported Q1 2026 revenue of $164.9 million, up from $157.2 million in the prior year, indicating sustained market demand that is expected to enhance future profitability.
- Guidance Upgrade: Management raised the 2026 revenue guidance to $950 million to $1.05 billion, primarily driven by strong performance in the endocrinology business and the new oncology drug Lifyorli, reflecting confidence in future growth.
- FDA Approval Impact: Lifyorli was included in the National Comprehensive Cancer Network (NCCN) guidelines just 15 days post-FDA approval, which is expected to accelerate market adoption and enhance the company's competitiveness in oncology.
- Long-term Growth Outlook: Management anticipates that the Cushing's Syndrome business will reach at least $2 billion in annual revenue by 2030, while Lifyorli is expected to exceed $1 billion in annual revenue in the U.S., demonstrating strong confidence in future market potential.
See More
CORCEPT THERAPEUTICS INC ANTICIPATES PROFITABILITY BY Q2 2026
Company Overview: Corcept Therapeutics is anticipating a return to profitability in the second quarter of 2026.
Financial Expectations: The company is focusing on strategies to enhance its financial performance and achieve sustainable growth.
See More
Corcept Lawsuit Reminder for Investors
- Lawsuit Timeline: Rosen Law Firm reminds investors who purchased Corcept (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors can join the class action without any upfront fees or costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Case Background: The lawsuit alleges that Corcept made false statements regarding the confidence in FDA approval for its drug relacorilant, despite the FDA expressing concerns about the adequacy of clinical evidence, which exposed investors to potential losses.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved multiple large settlements, recovering over $438 million for investors in 2019 alone, demonstrating its expertise and successful track record in this field.
See More
